PLSA1
MCID: PRM092
MIFTS: 38

Primary Lateral Sclerosis, Adult, 1 (PLSA1)

Categories: Genetic diseases, Mental diseases, Muscle diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Primary Lateral Sclerosis, Adult, 1

MalaCards integrated aliases for Primary Lateral Sclerosis, Adult, 1:

Name: Primary Lateral Sclerosis, Adult, 1 57 13 71
Adult-Onset Primary Lateral Sclerosis 58
Primary Lateral Sclerosis 58
Lateral Sclerosis 71
Pls, Adult; Plsa 57
Adult-Onset Pls 58
Pls, Adult 57
Plsa1 57
Plsa 57
Pls 58

Characteristics:

Orphanet epidemiological data:

58
primary lateral sclerosis
Inheritance: Autosomal recessive,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
autosomal dominant

Miscellaneous:
slowly progressive
average age at onset between 40 and 50 years


HPO:

31
primary lateral sclerosis, adult, 1:
Inheritance autosomal dominant inheritance
Onset and clinical course adult onset slow progression


Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

OMIM® 57 611637
ICD10 via Orphanet 33 G12.2
UMLS via Orphanet 72 C0154682 C1968845
Orphanet 58 ORPHA35689
MedGen 41 C1968845
UMLS 71 C0154682 C1968845

Summaries for Primary Lateral Sclerosis, Adult, 1

OMIM® : 57 Although primary lateral sclerosis (PLS) is similar to amyotrophic lateral sclerosis (ALS; 105400), they are considered to be clinically distinct progressive paralytic neurodegenerative disorders. Following a period of diagnostic confusion, the clinical distinction between ALS and PLS became clear and diagnostic criteria were established (Pringle et al., 1992). PLS is characterized by degeneration of the upper motor neurons and the corticospinal and corticobulbar tracts, whereas ALS is a more severe disorder characterized by degeneration of both the upper and lower motor neurons. See 606353 for autosomal recessive juvenile-onset PLS, which is caused by mutations in the ALS2 gene (606352). (611637) (Updated 05-Mar-2021)

MalaCards based summary : Primary Lateral Sclerosis, Adult, 1, also known as adult-onset primary lateral sclerosis, is related to lateral sclerosis and papillon-lefevre syndrome, and has symptoms including upper motor neuron signs An important gene associated with Primary Lateral Sclerosis, Adult, 1 is SPG7 (SPG7 Matrix AAA Peptidase Subunit, Paraplegin). The drugs Mexiletine and Olanzapine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and spinal cord, and related phenotypes are dysphagia and babinski sign

Related Diseases for Primary Lateral Sclerosis, Adult, 1

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Primary Lateral Sclerosis, Adult, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 lateral sclerosis 11.6
2 papillon-lefevre syndrome 11.6
3 primary lateral sclerosis, juvenile 11.5
4 spinal muscular atrophy, type iii 11.1
5 spinal muscular atrophy, type iv 11.1
6 infantile-onset ascending hereditary spastic paralysis 11.1
7 proximal spinal muscular atrophy 11.1
8 haim-munk syndrome 11.0
9 motor neuron disease 11.0
10 pleomorphic liposarcoma 11.0
11 potocki-lupski syndrome 10.9
12 proteus-like syndrome 10.9
13 hereditary spastic paraplegia 10.4
14 spastic paraparesis 10.3
15 amyotrophic lateral sclerosis 1 10.3
16 pseudobulbar affect 10.3
17 supranuclear palsy, progressive, 1 10.2
18 parkinsonism 10.2
19 pseudobulbar palsy 10.2
20 spastic paraplegia 7, autosomal recessive 10.2
21 polydactyly 10.1
22 periodontitis 10.1
23 spasticity 10.1
24 aphasia 10.1
25 quadriplegia 10.1
26 mills syndrome 10.1
27 frontotemporal dementia 10.1
28 ataxia and polyneuropathy, adult-onset 10.1
29 paraplegia 10.1
30 als2-related disorders 10.1
31 aspiration pneumonia 10.0
32 hemiplegia 10.0
33 spastic quadriplegia 10.0
34 cerebral atrophy 10.0
35 rare neurodegenerative disease 10.0
36 keratosis 10.0
37 polykaryocytosis inducer 10.0
38 candidiasis, familial, 1 9.9
39 chagas disease 9.9
40 septic arthritis 9.9
41 dysphagia 9.9
42 benign idiopathic neonatal seizures 9.9
43 pik3ca-related overgrowth syndrome 9.9
44 coronary ostial stenosis or atresia 9.9
45 macroglossia 9.9
46 parkinson disease, late-onset 9.9
47 spastic paraplegia 4, autosomal dominant 9.9
48 syringomyelia, noncommunicating isolated 9.9
49 tay-sachs disease 9.9
50 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 9.9

Comorbidity relations with Primary Lateral Sclerosis, Adult, 1 via Phenotypic Disease Network (PDN):


Acute Cystitis Intermittent Claudication

Graphical network of the top 20 diseases related to Primary Lateral Sclerosis, Adult, 1:



Diseases related to Primary Lateral Sclerosis, Adult, 1

Symptoms & Phenotypes for Primary Lateral Sclerosis, Adult, 1

Human phenotypes related to Primary Lateral Sclerosis, Adult, 1:

58 31 (show all 20)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 58 31 Frequent (79-30%) HP:0002015
2 babinski sign 58 31 Very frequent (99-80%) HP:0003487
3 spastic gait 58 31 Frequent (79-30%) HP:0002064
4 abnormal upper motor neuron morphology 58 31 Very frequent (99-80%) HP:0002127
5 spastic dysarthria 58 31 Frequent (79-30%) HP:0002464
6 spasticity 58 Very frequent (99-80%)
7 hyperreflexia 31 HP:0001347
8 upper motor neuron dysfunction 58 Very frequent (99-80%)
9 spastic tetraparesis 31 HP:0001285
10 sensory impairment 58 Excluded (0%)
11 loss of speech 58 Frequent (79-30%)
12 motor axonal neuropathy 58 Occasional (29-5%)
13 emg: chronic denervation signs 58 Frequent (79-30%)
14 atrophy of the spinal cord 58 Occasional (29-5%)
15 pseudobulbar signs 58 Frequent (79-30%)
16 cervical spinal cord atrophy 58 Occasional (29-5%)
17 abnormal lower motor neuron morphology 58 Excluded (0%)
18 progressive spastic paraparesis 58 Frequent (79-30%)
19 generalized hyperreflexia 58 Very frequent (99-80%)
20 weakness due to upper motor neuron dysfunction 58 Frequent (79-30%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neurologic Central Nervous System:
hyperreflexia
spastic tetraparesis
spastic gait
spastic dysarthria
upper motor neuron signs
more
Neurologic Peripheral Nervous System:
no sensory abnormalities

Abdomen Gastrointestinal:
dysphagia

Clinical features from OMIM®:

611637 (Updated 05-Mar-2021)

UMLS symptoms related to Primary Lateral Sclerosis, Adult, 1:


upper motor neuron signs

Drugs & Therapeutics for Primary Lateral Sclerosis, Adult, 1

Drugs for Primary Lateral Sclerosis, Adult, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 326)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
2
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585 135398745
3
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
4
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
5
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
6
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
7
Ceftriaxone Approved Phase 3 73384-59-5 5479530 5361919
8
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
9
Mecasermin Approved, Investigational Phase 3 68562-41-4
10
Acetylcholine Approved, Investigational Phase 2, Phase 3 51-84-3 187
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Quinidine Approved, Investigational Phase 3 56-54-2 441074
13
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
14
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
15
Citalopram Approved Phase 3 59729-33-8 2771
16
Edaravone Approved, Investigational Phase 3 89-25-8 70335
17
Iron Approved Phase 2, Phase 3 7439-89-6 23925 29936
18
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
19
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
20
Trazodone Approved, Investigational Phase 2, Phase 3 19794-93-5 5533
21
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
22
Sodium citrate Approved, Investigational Phase 3 68-04-2
23
Coal tar Approved Phase 2, Phase 3 8007-45-2
24
Pramipexole Approved, Investigational Phase 3 104632-26-0 59868 119570
25
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
26
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
27
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
28
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
29
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
31
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
32
Simendan Investigational Phase 3 131741-08-7
33 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
34 Nabiximols Investigational Phase 2, Phase 3 56575-23-6
35
Ibudilast Investigational Phase 2, Phase 3 50847-11-5 3671
36
Tauroursodeoxycholic acid Experimental, Investigational Phase 2, Phase 3 14605-22-2 12443252
37 Respiratory System Agents Phase 3
38 Analgesics Phase 2, Phase 3
39 Diuretics, Potassium Sparing Phase 3
40 Sodium Channel Blockers Phase 3
41 Anti-Arrhythmia Agents Phase 3
42 Vitamin B 12 Phase 2, Phase 3
43 Vitamin B12 Phase 2, Phase 3
44 Cardiotonic Agents Phase 3
45 Phosphodiesterase 3 Inhibitors Phase 3
46 Immunologic Factors Phase 3
47 Anti-Infective Agents Phase 3
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
49 Cephalosporins Phase 3
50 Ubiquinone Phase 3

Interventional clinical trials:

(show top 50) (show all 589)
# Name Status NCT ID Phase Drugs
1 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
2 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
3 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
4 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
5 Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
6 Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study Unknown status NCT03548311 Phase 3 methylcobalamin;saline solution
7 A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
8 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS Completed NCT03505021 Phase 3 Levosimendan;Placebo for levosimendan
9 A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis Completed NCT03491462 Phase 3 Arimoclomol;Placebo oral capsule
10 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
11 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
12 Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. Completed NCT00372879 Phase 3
13 Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00349622 Phase 3 ceftriaxone
14 A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner. Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
15 A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS Completed NCT00136110 Phase 3 Sodium Valproate
16 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
17 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
18 Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib Completed NCT02588677 Phase 2, Phase 3 Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
19 Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS) Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
20 An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT01285583 Phase 2, Phase 3 TRO19622
21 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
22 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
23 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
24 An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
25 A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
26 A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis Completed NCT00021697 Phase 3 AVP-923
27 The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013 Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
28 An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
29 Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
30 A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
31 Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2 Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
32 A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS Completed NCT03280056 Phase 3
33 Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS: Open-Label Extension for Patients Completing Study 3119002 Completed NCT03948178 Phase 3 Levosimendan
34 Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
35 Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS Completed NCT03127514 Phase 2, Phase 3 AMX0035
36 A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031) Completed NCT02936635 Phase 3 tirasemtiv
37 Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT00868166 Phase 3 Olesoxime;Placebo Comparator;Riluzole
38 A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT02496767 Phase 3 Tirasemtiv;Placebo tablets
39 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
40 An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis Completed NCT00965497 Phase 3 escitalopram
41 A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
42 A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy Completed NCT01951924 Phase 3 Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
43 Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Recruiting NCT04302870 Phase 2, Phase 3 Memantine Hydrochloride Oral Solution;Trazodone Hydrochloride oral solution;Placebo oral solution
44 Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone Recruiting NCT03293069 Phase 2, Phase 3 Deferiprone;Placebo Oral Tablet
45 A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS) Recruiting NCT04577404 Phase 3 MT-1186
46 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS) Recruiting NCT04248465 Phase 3 Placebo
47 Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) Recruiting NCT03800524 Phase 3 Tauroursodeoxycholic Acid;Placebo
48 HEALEY ALS Platform Trial Recruiting NCT04297683 Phase 2, Phase 3 Zilucoplan;Verdiperstat;CNM-Au8;Pridopidine
49 A Double-blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Lenzumestrocel(Neuronata-R® Inj.) in Patients With Amyotrophic Lateral Sclerosis Recruiting NCT04745299 Phase 3 Riluzole
50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Cu(II)ATSM in Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Recruiting NCT04082832 Phase 2, Phase 3 Cu(II)ATSM;Placebos

Search NIH Clinical Center for Primary Lateral Sclerosis, Adult, 1

Genetic Tests for Primary Lateral Sclerosis, Adult, 1

Anatomical Context for Primary Lateral Sclerosis, Adult, 1

MalaCards organs/tissues related to Primary Lateral Sclerosis, Adult, 1:

40
Bone Marrow, Bone, Spinal Cord, Tongue, Eye, Skin, Cortex

Publications for Primary Lateral Sclerosis, Adult, 1

Articles related to Primary Lateral Sclerosis, Adult, 1:

# Title Authors PMID Year
1
A locus for primary lateral sclerosis on chromosome 4ptel-4p16.1. 57
18332252 2008
2
Adult-onset primary lateral sclerosis is not associated with mutations in the ALS2 gene. 57
17698795 2007
3
Autosomal dominant primary lateral sclerosis. 57
17404201 2007
4
Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. 57
1606479 1992
5
Global ecological patterns in uncultured Archaea. 61
19847207 2010

Variations for Primary Lateral Sclerosis, Adult, 1

Expression for Primary Lateral Sclerosis, Adult, 1

Search GEO for disease gene expression data for Primary Lateral Sclerosis, Adult, 1.

Pathways for Primary Lateral Sclerosis, Adult, 1

GO Terms for Primary Lateral Sclerosis, Adult, 1

Sources for Primary Lateral Sclerosis, Adult, 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....